| 1 |
Abed T, Ganser K, Eckert F, Stransky N, Huber SM. Ion channels as molecular targets of glioblastoma electrotherapy. Front Cell Neurosci 2023;17. [DOI: 10.3389/fncel.2023.1133984] [Reference Citation Analysis]
|
| 2 |
Vergote I, Macarulla T, Hirsch FR, Hagemann C, Miller DS. Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment. Cancers (Basel) 2023;15. [PMID: 36765594 DOI: 10.3390/cancers15030636] [Reference Citation Analysis]
|
| 3 |
Nishikawa R, Yamasaki F, Arakawa Y, Muragaki Y, Narita Y, Tanaka S, Yamaguchi S, Mukasa A, Kanamori M. Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study. Jpn J Clin Oncol 2023:hyad001. [PMID: 36647599 DOI: 10.1093/jjco/hyad001] [Reference Citation Analysis]
|
| 4 |
Di Gregorio E, Israel S, Staelens M, Tankel G, Shankar K, Tuszyński JA. The distinguishing electrical properties of cancer cells. Phys Life Rev 2022;43:139-88. [PMID: 36265200 DOI: 10.1016/j.plrev.2022.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Nitta RT, Luo EJ, Lim M, Li G. Can tumor treating fields induce DNA damage and reduce cell motility in medulloblastoma cell lines? J Neurosurg Pediatr 2022;30:555-66. [PMID: 36208441 DOI: 10.3171/2022.8.PEDS22300] [Reference Citation Analysis]
|
| 6 |
Xie D, Wang Q, Wu G. Research progress in inducing immunogenic cell death of tumor cells. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1017400] [Reference Citation Analysis]
|
| 7 |
Barsheshet Y, Voloshin T, Brant B, Cohen G, Koren L, Blatt R, Cahal S, Haj Khalil T, Zemer Tov E, Paz R, Klein-Goldberg A, Tempel-Brami C, Jacobovitch S, Volodin A, Kan T, Koltun B, David C, Haber A, Giladi M, Weinberg U, Palti Y. Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model. Int J Mol Sci 2022;23. [PMID: 36430552 DOI: 10.3390/ijms232214073] [Reference Citation Analysis]
|
| 8 |
Moser JC, Salvador E, Deniz K, Swanson K, Tuszynski J, Carlson KW, Karanam NK, Patel CB, Story M, Lou E, Hagemann C. The Mechanisms of Action of Tumor Treating Fields. Cancer Res 2022;82:3650-8. [PMID: 35839284 DOI: 10.1158/0008-5472.CAN-22-0887] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 9 |
Tanzhu G, Chen L, Xiao G, Shi W, Peng H, Chen D, Zhou R. The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy. Cell Death Discov 2022;8:416. [PMID: 36220835 DOI: 10.1038/s41420-022-01206-y] [Reference Citation Analysis]
|
| 10 |
Salvador E, Kessler AF, Domröse D, Hörmann J, Schaeffer C, Giniunaite A, Burek M, Tempel-brami C, Voloshin T, Volodin A, Zeidan A, Giladi M, Ernestus R, Löhr M, Förster CY, Hagemann C. Tumor Treating Fields (TTFields) Reversibly Permeabilize the Blood–Brain Barrier In Vitro and In Vivo. Biomolecules 2022;12:1348. [DOI: 10.3390/biom12101348] [Reference Citation Analysis]
|
| 11 |
Le HT, Staelens M, Lazzari D, Chan G, Tuszyński JA. Real-Time Monitoring of the Effect of Tumour-Treating Fields on Cell Division Using Live-Cell Imaging. Cells 2022;11:2712. [DOI: 10.3390/cells11172712] [Reference Citation Analysis]
|
| 12 |
Shams S, Patel CB. Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]). J Mol Cell Biol 2022;14. [PMID: 35973687 DOI: 10.1093/jmcb/mjac047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Guo X, Yang X, Wu J, Yang H, Li Y, Li J, Liu Q, Wu C, Xing H, Liu P, Wang Y, Hu C, Ma W. Tumor-Treating Fields in Glioblastomas: Past, Present, and Future. Cancers 2022;14:3669. [DOI: 10.3390/cancers14153669] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 14 |
Mannarino L, Mirimao F, Panini N, Paracchini L, Marchini S, Beltrame L, Amodeo R, Grosso F, Libener R, De Simone I, Ceresoli GL, Zucali PA, Lupi M, D'Incalci M. Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations. Cell Death Dis 2022;13:612. [PMID: 35840560 DOI: 10.1038/s41419-022-05073-4] [Reference Citation Analysis]
|
| 15 |
Yang M, Brackenbury WJ. Harnessing the Membrane Potential to Combat Cancer Progression. Bioelectricity. [DOI: 10.1089/bioe.2022.0001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Bomzon Z. Treating solid tumors using tumor treating fields. Principles and Technologies for Electromagnetic Energy Based Therapies 2022. [DOI: 10.1016/b978-0-12-820594-5.00004-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Hong P, Kudulaiti N, Wu S, Nie J, Zhuang D. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism. Expert Rev Mol Diagn 2021;:1-10. [PMID: 34883030 DOI: 10.1080/14737159.2022.2017283] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Jones TH, Song JW, Abushahin L. Tumor treating fields: An emerging treatment modality for thoracic and abdominal cavity cancers. Transl Oncol 2022;15:101296. [PMID: 34847422 DOI: 10.1016/j.tranon.2021.101296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 19 |
Arvind R, Chandana SR, Borad MJ, Pennington D, Mody K, Babiker H. Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates. Crit Rev Oncol Hematol 2021;168:103535. [PMID: 34808377 DOI: 10.1016/j.critrevonc.2021.103535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Hasanzadeh N, Niknejad A. Cerebral Glioblastoma: A Review on Genetic Alterations, Signaling Pathways, and Clinical Managements. Jentashapir J Cell Mol Biol 2021;12. [DOI: 10.5812/jjcmb.119223] [Reference Citation Analysis]
|
| 21 |
Zaki I, Abou-Elkhair RAI, Abu Almaaty AH, A Abu Ali O, Fayad E, Ahmed Gaafar AG, Zakaria MY. Design and Synthesis of Newly Synthesized Acrylamide Derivatives as Potential Chemotherapeutic Agents against MCF-7 Breast Cancer Cell Line Lodged on PEGylated Bilosomal Nano-Vesicles for Improving Cytotoxic Activity. Pharmaceuticals (Basel) 2021;14:1021. [PMID: 34681245 DOI: 10.3390/ph14101021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 22 |
Aguilar AA, Ho MC, Chang E, Carlson KW, Natarajan A, Marciano T, Bomzon Z, Patel CB. Permeabilizing Cell Membranes with Electric Fields. Cancers (Basel) 2021;13:2283. [PMID: 34068775 DOI: 10.3390/cancers13092283] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 23 |
Zacksenhaus E, Egan SE. Progression to Metastasis of Solid Cancer. Cancers (Basel) 2021;13:717. [PMID: 33578666 DOI: 10.3390/cancers13040717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 24 |
Connor K, Murray DW, Jarzabek MA, Tran NL, White K, Dicker P, Sweeney KJ, O'Halloran PJ, MacCarthy B, Shiels LP, Lodi F, Lambrechts D, Sarkaria JN, Schiffelers RM, Symons M, Byrne AT. Targeting the RhoGEF βPIX/COOL-1 in Glioblastoma: Proof of Concept Studies. Cancers (Basel) 2020;12:E3531. [PMID: 33256106 DOI: 10.3390/cancers12123531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
